These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10160489)

  • 21. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
    Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
    PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact of influenza vaccination in preschool children.
    Cohen GM; Nettleman MD
    Pediatrics; 2000 Nov; 106(5):973-6. PubMed ID: 11061762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-influenza vaccination for active persons (25-64 years): a cost-benefit study].
    Levy E; Levy P
    Rev Epidemiol Sante Publique; 1992; 40(5):285-95. PubMed ID: 1480805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs and effectiveness of influenza vaccination: a systematic review.
    D'Angiolella LS; Lafranconi A; Cortesi PA; Rota S; Cesana G; Mantovani LG
    Ann Ist Super Sanita; 2018; 54(1):49-57. PubMed ID: 29616674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance].
    Hak E; Knol LM; Wilschut JC; Postma MJ
    Ned Tijdschr Geneeskd; 2010; 154():A1188. PubMed ID: 20977784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
    Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.
    Ott JJ; Klein Breteler J; Tam JS; Hutubessy RC; Jit M; de Boer MR
    Hum Vaccin Immunother; 2013 Jul; 9(7):1500-11. PubMed ID: 23732900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmaco-economics of anti-influenza vaccinations].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2003 Jun; 14(84):679-81. PubMed ID: 14524303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza cost and cost-effectiveness studies globally--a review.
    Peasah SK; Azziz-Baumgartner E; Breese J; Meltzer MI; Widdowson MA
    Vaccine; 2013 Nov; 31(46):5339-48. PubMed ID: 24055351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the impact of influenza vaccination. A North American perspective.
    Fedson DS
    Pharmacoeconomics; 1996; 9 Suppl 3():54-61. PubMed ID: 10160488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic review].
    Valcárcel Nazco C; García Lorenzo B; Del Pino Sedeño T; García Pérez L; Brito García N; Linertová R; Ferrer Rodríguez J; Imaz Iglesia I; Serrano Aguilar P
    Rev Esp Salud Publica; 2018 Oct; 92():. PubMed ID: 30327454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination.
    Quinn E; Jit M; Newall AT
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):425-35. PubMed ID: 24734967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of vaccination against influenza in New Zealand.
    Scott WG; Scott HM
    Pharmacoeconomics; 1996 Jan; 9(1):51-60. PubMed ID: 10160087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH; Wong WC; Ip M; Lee NL; Ho SC
    J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.
    Smith KJ; Nowalk MP; Lin CJ; Zimmerman RK
    Hum Vaccin Immunother; 2017 Oct; 13(10):2207-2212. PubMed ID: 28829719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.